AI Article Synopsis
- The study examines the effectiveness of intralesional curettage and phenol treatment for atypical cartilaginous tumors (ACT), focusing on disease-specific and progression-free survival rates.
- Researchers analyzed data from 388 ACT patients over nearly two decades, finding that 14% had residual disease, with a quarter showing continued tumor growth after treatment.
- While no cases of malignant progression or mortality were recorded, complications like postoperative fractures and the need for additional surgeries were common, indicating a need for more research on ACT management strategies.
Article Abstract
Background And Purpose: Despite evolving management strategies for atypical cartilaginous tumors (ACT)-shifting from radical resection to intralesional curettage and "wait-and-scan" approaches-there remains no universal consensus on optimal treatment. We primarily aimed to evaluate disease-specific and progression-free survival following intralesional curettage and adjuvant phenol treatment of ACTs. Secondary aims included assessing surgical complications, the need for additional interventions, and an overview of long-term follow-up.
Methods: This retrospective cohort study of 388 ACT patients was conducted at a tertiary referral center from 2000 to 2019. Comprehensive data collection included demographics, tumor characteristics, and follow-up outcomes.
Results: Residual disease was observed in 14% (n = 53) of cases, with continued growth on sequential imaging in one-fourth (n = 13 of 53). Postoperative fractures occurred in 10% (n = 37) after a mean of 7 months, and 16% (n = 61) required a second surgery due to pain or joint movement limitations. There was no malignant progression or mortality observed.
Conclusion: We found that curettage for ACT is not associated with mortality or malignant progression but does carry risks of complications and residual disease. This raises important questions regarding the necessity of surgical intervention. Further research is needed to refine the treatment approach for ACT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/17453674.2024.42636 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcome of curettage in atypical cartilaginous tumors of the long bones: a descriptive cohort study.
Acta Orthop
December 2024
Department of Orthopedics, University Hospital Ghent, Ghent, Belgium.
Background And Purpose: Despite evolving management strategies for atypical cartilaginous tumors (ACT)-shifting from radical resection to intralesional curettage and "wait-and-scan" approaches-there remains no universal consensus on optimal treatment. We primarily aimed to evaluate disease-specific and progression-free survival following intralesional curettage and adjuvant phenol treatment of ACTs. Secondary aims included assessing surgical complications, the need for additional interventions, and an overview of long-term follow-up.
View Article and Find Full Text PDFOptimal Magnetic Resonance Sequence for Assessment of Central Cartilage Tumor Scalloping.
Indian J Radiol Imaging
January 2025
Department of Musculoskeletal Radiology, Royal Orthopedic Hospital, Birmingham, United Kingdom.
Magnetic resonance imaging (MRI) is key in evaluating central cartilage tumors. The BACTIP (Birmingham Atypical Cartilaginous Tumour Imaging Protocol) protocol assesses central cartilage tumor risk based on the tumor size and degree of endosteal scalloping on MRI. It provides a management protocol for assessment, follow-up, or referral of central cartilage tumors.
View Article and Find Full Text PDFAggressive Mesenchymal Chondrosarcoma of the Rib With Early Skeletal Metastases: A Diagnostic Challenge.
Cureus
November 2024
Internal Medicine, Centro Hospitalar Tondela Viseu, Viseu, PRT.
Mesenchymal chondrosarcoma (MCS) is a rare, aggressive subtype of chondrosarcoma characterized by biphasic histology, often misdiagnosed due to its rarity and histological resemblance to other small round cell tumors. It predominantly affects adolescents and young adults. We report a 27-year-old male presenting with a progressively enlarging, painless mass in the right inframammary region, initially attributed to muscular strain.
View Article and Find Full Text PDFEvaluation of the value of dynamic contrast-enhanced MRI for the diagnosis and follow-up of central cartilage tumors.
Eur J Radiol
November 2024
Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel, Heymanslaan 10, 9000 Ghent, Belgium.
Objectives: To evaluate the value of (dynamic) contrast-enhanced MRI for the diagnosis and follow-up of central cartilage tumors (CCT) of the proximal humerus, distal femur and proximal tibia.
Materials & Methods: 97 patients (44 ± 11 years, 31men) with a CCT (histopathologically proven and/or > 2 years follow-up (5 ± 3 years)) were retrospectively/consecutively included at the Ghent University Hospital (Belgium, 2003-2021). Thickness of the enhancing rim and dynamic contrast-enhanced MRI parameters of the entire tumor were calculated.
Sacral nerve preservation on total sacrectomy of a large atypical sacral chordoma resection: A case report.
Int J Surg Case Rep
November 2024
Department of Orthopaedics and Traumatology, Faculty of medicine Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia.
Article Synopsis
- - Chordoma is a slow-growing, benign tumor that rarely occurs in the spine, but can cause significant neurological issues due to its mass effect on the spinal cord or nerves when symptomatic.
- - A case involving a 39-year-old male highlighted a chordoma in the sacral region, which caused pain and dysfunction, leading to surgical removal and stabilization, despite a complication during the procedure.
- - Post-surgery, the patient showed good outcomes with minimal pain and no issues with bowel or bladder function, emphasizing the potential for effective management and early mobilization following lumbopelvic stabilization.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!